Brief Title
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
Official Title
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
Brief Summary
Analysis of mucus, mucin and DNA concentration, MUC5B/5AC ratio, rheology, osmotic pressure, cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy individuals and those with bronchiectasis. (60 total)
Detailed Description
In this study the investigators will investigate the mucus properties in individuals with idiopathic bronchiectasis and healthy individuals without a history of lung disease. In order to understand how mucus is abnormal in disease conditions, the investigators need to understand the mucus biochemical and biophysical properties in healthy individuals. In this study the investigators will prospectively recruit patients with bronchiectasis and healthy individuals from the community to provide airway sputum samples. In these samples the investigators will measure an array of mucus properties. This will help our understanding of the mucus-obstructive lung diseases and facilitate the development of appropriate and effective disease prevention strategies. A key question is whether mucus is hyper-concentrated and has abnormal biophysical properties in individuals with mucus-obstructive lung disease. To answer this question, the investigators need to understand the properties of the mucus in individuals with idiopathic bronchiectasis and no history of lung disease. This study will allow us to collect airway mucus (sputum) from individuals with bronchiectasis and healthy individuals with no history of lung disease.
Study Type
Observational
Primary Outcome
Mucus concentration (% solids)
Secondary Outcome
Biophysical properties of mucus by rheology
Condition
Bronchiectasis Adult
Study Arms / Comparison Groups
control
Description: healthy individuals with no history of lung disease
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
30
Start Date
March 10, 2017
Completion Date
June 27, 2017
Primary Completion Date
June 27, 2017
Eligibility Criteria
Participants who meet all the following criteria are eligible for the study: - Written informed consent - Bronchiectasis patients: Available CT of the chest that shows evidence of dilated airways fulfilling radiographic criteria for bronchiectasis in more than one lobe and chronic cough. Participants who meet any of the following criteria will not be eligible for the study: - Healthy individuals: A history of lung disease, current asthma symptoms or medication use, premature birth (<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness, current smoker or a history of smoking tobacco products. - Bronchiectasis patients: Premature birth (<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness. - Younger than 18 years of age
Gender
All
Ages
18 Years - 99 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Richard Boucher, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT03125174
Organization ID
16-3142
Responsible Party
Sponsor
Study Sponsor
University of North Carolina, Chapel Hill
Study Sponsor
Richard Boucher, MD, Study Chair, University of North Carolina, Chapel Hill
Verification Date
July 2017